CLARISCAN 376.9 mg/mL (Gadoterate Meglumine INJECTION, SOLUTION) 376.9 mg/mL

Clariscan 376.9 mg/mL is a gadoterate meglumine injection solution used for magnetic resonance imaging (MRI). This contrast agent enhances image clarity, aiding in diagnostic procedures. Ideal for healthcare professionals seeking reliable MRI contrast.

Strength

376.9 mg/mL

Pack Size

10 VIAL, GLASS in 1 BOX (0407-2943-01) / 10 mL in 1 VIAL, GLASS

Manufacturer / TM Owner

GE Healthcare

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Clariscan 376.9 mg/mL is primarily used as a contrast agent in MRI scans. It helps to improve the visibility of internal body structures, making it easier for healthcare providers to diagnose and monitor various conditions. What is Clariscan used for? It is commonly utilized in MRI procedures to enhance image quality and provide clearer diagnostic images.

Side Effects

Clariscan 376.9 mg/mL may cause common effects such as nausea, headache, or a warm sensation during administration. These effects are typically mild and temporary. Some individuals may experience more severe reactions, though these are less common.

Precautions & Warnings

Clariscan 376.9 mg/mL should be used with caution in individuals with kidney problems or a history of allergic reactions to contrast agents. It is important to inform healthcare providers about any existing medical conditions or allergies before administration. Proper handling and storage are essential to maintain the integrity of the solution.

Avoid Interactions

Clariscan 376.9 mg/mL may interact with certain medications or substances. It is important to discuss all current medications with a healthcare provider before using this contrast agent. Alcohol and other substances that affect kidney function should be avoided to minimize potential interactions.

References

Frequently Asked Questions

Clariscan is used as a contrast agent in MRI scans to enhance image clarity and aid in diagnostic procedures.

Clariscan is administered intravenously by a healthcare professional during an MRI procedure.

Common side effects may include nausea, headache, or a warm sensation during administration.

Individuals with kidney problems or a history of allergic reactions to contrast agents should use Clariscan with caution.

Clariscan should be stored as per the manufacturer's instructions to maintain its effectiveness.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.